专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20080280831A1 Chimeric proteins with phosphatidylserine binding domains 有权
标题翻译：嵌合蛋白与磷脂酰丝氨酸结合结构域
公开(公告)号：US20080280831A1
公开(公告)日：2008-11-13
申请号：US12157525
申请日：2008-06-11
申请人： Stuart E. Lind , Wei-Qun Ding , Roger G. Harrison
发明人： Stuart E. Lind , Wei-Qun Ding , Roger G. Harrison
IPC分类号： A61K38/16 , A61P7/04
CPC分类号： C07K14/70596 , A01K67/027 , A01K2267/0375 , A61K38/00 , C07K14/4721 , C07K14/745 , C07K2319/33 , C12N9/6437 , C12Y304/21021
摘要： Chimeric proteins comprising soluble Tissue Factor (sTF) and another subunit (e.g., annexin V) are described. The proteins promote blood clotting and/or inhibit cancer by targeting sTF to specific receptors such as phosphatidylserine (PS) on activated cells. These chimeric proteins are useful in treating patients with excessive bleeding due to inborn problems, drug therapy, trauma or surgery and/or as an anti-cancer therapy, for example by causing blood vessels feeding cancers to become clotted, thereby preventing adequate flow of blood to a tumor, which in turn will lead to tumor inhibition and death or may be used in a therapy to cause clotting within blood vessels that pose a threat in the subject in non-cancerous conditions.
摘要翻译：描述了包含可溶性组织因子（sTF）和另一亚基（例如膜联蛋白V）的嵌合蛋白。蛋白质通过将sTF靶向特异性受体（例如活化细胞上的磷脂酰丝氨酸（PS））来促进血液凝固和/或抑制癌症。这些嵌合蛋白质可用于治疗由于先天性问题，药物治疗，创伤或外科手术和/或作为抗癌治疗引起的过度出血的患者，例如通过使血管供体癌症变得凝结，从而防止足够的血液流动到肿瘤，其又将导致肿瘤抑制和死亡，或者可以用于治疗以在非癌症状况下对受试者造成威胁的血管内的凝血。

2. 发明授权

US4143047A 2-Sulfinyl and 2-sulfonyl oxazoles 失效
标题翻译： 2-磺酰基和2-磺酰氧基
公开(公告)号：US4143047A
公开(公告)日：1979-03-06
申请号：US836284
申请日：1977-09-26
申请人： Roger G. Harrison
发明人： Roger G. Harrison
IPC分类号： C07D263/34 , C07D263/46 , C07D263/48
CPC分类号： C07D263/34 , C07D263/46 , C07D263/48
摘要： Oxazoles having a sulfinyl or sulfonyl substituent at the 2-position are provided. Such compounds readily react with an alkali metal salt of a secondary amide in a method of making 2-acylamino oxazole derivatives having anti-allergic activity.

3. 发明申请

US20080227687A1 COMPOSITION AND METHOD FOR CANCER TREATMENT USING TARGETED SINGLE-WALLED CARBON NANOTUBES 审中-公开
标题翻译：使用目标单壁碳纳米管进行癌症治疗的组合物和方法
公开(公告)号：US20080227687A1
公开(公告)日：2008-09-18
申请号：US12033857
申请日：2008-02-19
申请人： Roger G. Harrison , Daniel E. Resasco
发明人： Roger G. Harrison , Daniel E. Resasco
IPC分类号： A61K38/00 , A61B18/18
CPC分类号： A61K38/1709 , A61K41/0052 , A61K47/6925 , A61N5/062 , A61N2005/0659 , B82Y5/00
摘要： The present invention is a method for detecting and destroying cancer tumors. The method is based on the concept of associating a linking protein or linking peptide such as, but not limited to, annexin V or other annexins to single-walled carbon nanotubes (SWNT) to form a protein-SWNT complex. Said linking protein or peptide can selectively bind to cancerous cells, especially tumor vasculature endothelial cells, rather than to healthy ones by binding to cancer-specific external receptors such as anionic phospholipids including phosphatidylserine expressed on the outer surfaces of cancer cells only. Irradiation of bound SWNTs with specific wavelength is then used to detect and destroy those cells to which the SWNTs are bound via the linking protein or peptide thereby destroying the tumor or cancer cells.
摘要翻译：本发明是一种检测和破坏癌症肿瘤的方法。该方法基于将连接蛋白或连接肽例如但不限于膜联蛋白V或其他膜联蛋白与单壁碳纳米管（SWNT）缔合以形成蛋白质-WWNT复合物的概念。所述连接蛋白或肽可以选择性地结合癌细胞，特别是肿瘤血管内皮细胞，而不是通过结合癌症特异性外部受体（例如仅在癌细胞的外表面上表达的磷脂酰丝氨酸的阴离子磷脂）结合而不是健康细胞。然后使用具有特定波长的结合的SWNT的照射来检测和破坏通过连接蛋白或肽结合SWNT的那些细胞，从而破坏肿瘤或癌细胞。

4. 发明授权

US5910319A Fluoxetine enteric pellets and methods for their preparation and use 失效
公开(公告)号：US5910319A
公开(公告)日：1999-06-08
申请号：US867196
申请日：1997-05-29
申请人： Neil R. Anderson , Roger G. Harrison , Daniel F. Lynch , Peter L. Oren
发明人： Neil R. Anderson , Roger G. Harrison , Daniel F. Lynch , Peter L. Oren
IPC分类号： A61K9/28 , A61K9/16 , A61K9/24 , A61K9/36 , A61K9/50 , A61K9/52 , A61K9/54 , A61K31/135 , A61K31/138 , A61K47/36 , A61K47/38 , A61P25/00 , A61P25/24 , A61P25/26 , C07C217/00
CPC分类号： A61K31/138 , A61K9/5078 , Y10S514/962
摘要： A superior enteric formulation of the antidepressant drug, fluoxetine, is in the form of enteric pellets of which the enteric layer comprises hydroxypropylmethylcellulose acetate succinate.

5. 发明申请

US20090304666A1 CONJUGATE FOR THE SPECIFIC TARGETING OF ANTICANCER AGENTS TO TUMOR CELLS OR TUMOR VASCULATURE AND PRODUCTION THEREOF 审中-公开
标题翻译：将肿瘤细胞特异性靶向肿瘤细胞或肿瘤血管并进行生产
公开(公告)号：US20090304666A1
公开(公告)日：2009-12-10
申请号：US12502011
申请日：2009-07-13
申请人： Roger G. Harrison , J. Thomas Pento , Stuart E. Lind
发明人： Roger G. Harrison , J. Thomas Pento , Stuart E. Lind
IPC分类号： A61K38/51 , A61P35/00 , C12N5/06
CPC分类号： A61K38/51 , A61K47/64 , A61K47/642 , C07K14/485 , C07K14/49 , C07K14/52 , C07K14/5406 , C07K14/5412 , C07K14/65 , C07K14/78 , C07K2319/55 , C07K2319/75
摘要： A conjugate is disclosed herein, wherein the conjugate includes a ligand having the ability to specifically and stably bind to an external receptor or binding site on a tumor vasculature endothelial cell, wherein the external receptor or binding site is specific for tumor vasculature endothelial cells. The conjugate also includes an anticancer agent that is selectively toxic to cancer cells operatively attached to the ligand. The anticancer agent may be L-methioninase. Pharmaceutical compositions comprising the conjugate are also disclosed, as well as methods of treating a cancer tumor or cancer cells with a therapeutically effective amount of the conjugate.
摘要翻译：本文公开了缀合物，其中所述缀合物包括具有特异性和稳定地结合肿瘤血管内皮细胞上的外部受体或结合位点的能力的配体，其中外部受体或结合位点对于肿瘤血管内皮细胞是特异性的。缀合物还包括对可操作地连接到配体的癌细胞有选择性毒性的抗癌剂。抗癌剂可以是L-蛋氨酸酶。还公开了包含缀合物的药物组合物，以及用治疗有效量的缀合物治疗癌症肿瘤或癌细胞的方法。

6. 发明授权

US4977140A Injectable sustained release formulation 失效
标题翻译：注射缓释制剂
公开(公告)号：US4977140A
公开(公告)日：1990-12-11
申请号：US327861
申请日：1989-03-23
申请人： Thomas H. Ferguson , Roger G. Harrison , David L. Moore
发明人： Thomas H. Ferguson , Roger G. Harrison , David L. Moore
IPC分类号： A61K9/00 , A61K38/27 , A61K47/44
CPC分类号： A61K38/27 , A61K47/44 , A61K9/0019 , Y10S514/964 , Y10S514/965
摘要： A dairy cow injected with a sustained release formulation comprising bovine somatotropin, a wax, and an oil produces more milk for 28 days.
摘要翻译：注射含有牛生长激素，蜡和油的持续释放制剂的奶牛产生更多的牛奶28天。

7. 发明授权

US08473611B1 Referrer cache chain 有权
标题翻译：引荐来源缓存链
公开(公告)号：US08473611B1
公开(公告)日：2013-06-25
申请号：US12554663
申请日：2009-09-04
申请人： Richard E. Meier , Roger G. Harrison , Todd Miller
发明人： Richard E. Meier , Roger G. Harrison , Todd Miller
IPC分类号： G06F15/173
CPC分类号： G06F17/30902
摘要： A request for content is received at a content filter of a computer system, and a determination is made, based on a referrer included in the request, regarding a root site directly or indirectly associated with the request. Thereafter, the content is permitted or not permitted according to whether or not the root site is a permitted site and a site associated with the content is categorized in a semantically equivalent content category with the root site. The determination regarding the root site may involve consulting a referrer chain cache storing lists of referrers which associate referring Web sites with root sites from which referrals originate.
摘要翻译：在计算机系统的内容过滤器处接收对内容的请求，并且基于包括在请求中的引用者，确定与请求直接或间接相关联的根站点。此后，根据站点是否是允许站点，允许还是不允许内容，并且与内容相关联的站点被分类为具有根站点的语义上等同的内容类别。关于根站点的确定可能涉及咨询引用者链缓存，其存储将引用网站与引用来源的根站点相关联的引用者的列表。

8. 发明授权

US07807644B2 Chimeric proteins with phosphatidylserine binding domains 有权
标题翻译：嵌合蛋白与磷脂酰丝氨酸结合结构域
公开(公告)号：US07807644B2
公开(公告)日：2010-10-05
申请号：US12157525
申请日：2008-06-11
申请人： Stuart E. Lind , Wei-Qun Ding , Roger G. Harrison
发明人： Stuart E. Lind , Wei-Qun Ding , Roger G. Harrison
IPC分类号： A61K38/00
CPC分类号： C07K14/70596 , A01K67/027 , A01K2267/0375 , A61K38/00 , C07K14/4721 , C07K14/745 , C07K2319/33 , C12N9/6437 , C12Y304/21021
摘要： Chimeric proteins comprising soluble Tissue Factor (sTF) and another subunit (e.g., annexin V) are described. The proteins promote blood clotting and/or inhibit cancer by targeting sTF to specific receptors such as phosphatidylserine (PS) on activated cells. These chimeric proteins are useful in treating patients with excessive bleeding due to inborn problems, drug therapy, trauma or surgery and/or as an anti-cancer therapy, for example by causing blood vessels feeding cancers to become clotted, thereby preventing adequate flow of blood to a tumor, which in turn will lead to tumor inhibition and death or may be used in a therapy to cause clotting within blood vessels that pose a threat in the subject in non-cancerous conditions.
摘要翻译：描述了包含可溶性组织因子（sTF）和另一亚基（例如膜联蛋白V）的嵌合蛋白。蛋白质通过将sTF靶向特异性受体（例如活化细胞上的磷脂酰丝氨酸（PS））来促进血液凝固和/或抑制癌症。这些嵌合蛋白质可用于治疗由于先天性问题，药物治疗，创伤或外科手术和/或作为抗癌治疗引起的过度出血的患者，例如通过使血管供体癌症变得凝结，从而防止足够的血液流动到肿瘤，其又将导致肿瘤抑制和死亡，或者可以用于治疗以在非癌症状况下对受试者造成威胁的血管内的凝血。

9. 发明授权

US4775659A Injectable semi-solid formulations 失效
标题翻译：注射半固体制剂
公开(公告)号：US4775659A
公开(公告)日：1988-10-04
申请号：US766725
申请日：1985-08-19
申请人： Arvind L. Thakkar , Roger G. Harrison
发明人： Arvind L. Thakkar , Roger G. Harrison
IPC分类号： A61K9/00 , A61K9/10 , A61K47/00 , A61K47/14 , A61K47/44 , A61K37/36 , A61K37/18
CPC分类号： A61K9/0024 , A61K47/14 , A61K47/44 , Y10S514/964
摘要： This invention provides injectable semi-solid formulations comprising a pharmaceutically or veterinary active agent, an oil and a suitable glyceride release modifying agent.
摘要翻译：本发明提供了包含药用或兽用活性剂，油和合适的甘油酯释放改性剂的可注射的半固体制剂。

10. 发明授权

US07393833B2 Chimeric proteins with phosphatidylserine binding domains 有权
标题翻译：嵌合蛋白与磷脂酰丝氨酸结合结构域
公开(公告)号：US07393833B2
公开(公告)日：2008-07-01
申请号：US11371872
申请日：2006-03-08
申请人： Stuart E. Lind , Wei-Qun Ding , Roger G. Harrison
发明人： Stuart E. Lind , Wei-Qun Ding , Roger G. Harrison
IPC分类号： A61K38/00
CPC分类号： C07K14/70596 , A01K67/027 , A01K2267/0375 , A61K38/00 , C07K14/4721 , C07K14/745 , C07K2319/33 , C12N9/6437 , C12Y304/21021
摘要： Chimeric proteins comprising soluble Tissue Factor (sTF) and another subunit (e.g., annexin V) are described. The proteins promote blood clotting and/or inhibit cancer by targeting sTF to specific receptors such as phosphatidyl serine (PS) on activated cells. These chimeric proteins are useful in treating patients with excessive bleeding due to inborn problems, drug therapy, trauma or surgery and/or as an anti-cancer therapy, for example by causing blood vessels feeding cancers to become clotted, thereby preventing adequate flow of blood to a tumor, which in turn will lead to tumor inhibition and death or may be used in a therapy to cause clotting within blood vessels that pose a threat in the subject in non-cancerous conditions.
摘要翻译：描述了包含可溶性组织因子（sTF）和另一亚基（例如膜联蛋白V）的嵌合蛋白。蛋白质通过将sTF靶向特定受体（例如活化细胞上的磷脂酰丝氨酸（PS））来促进血液凝固和/或抑制癌症。这些嵌合蛋白质可用于治疗由于先天性问题，药物治疗，创伤或外科手术和/或作为抗癌治疗引起的过度出血的患者，例如通过使血管供体癌症变得凝结，从而防止足够的血液流动到肿瘤，其又将导致肿瘤抑制和死亡，或者可以用于治疗以在非癌症状况下对受试者造成威胁的血管内的凝血。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式